expert Q&A
expert Q&A
03/25/2024

Peter G. Jacobs, PhD

Peter G. Jacobs, PhD
In this Q&A, study author Peter G. Jacobs, PhD, discusses the results of his team’s recent study examining the potential of combining wearable fitness sensor data with automated insulin delivery systems...
03/25/2024
expert Q&A
expert Q&A
03/25/2024

Peter G. Jacobs, PhD

Peter G. Jacobs, PhD
In this Q&A, study author Peter G. Jacobs, PhD, discusses the results of his team’s recent study examining the potential of combining wearable fitness sensor data with automated insulin delivery systems...
03/25/2024
expert Q&A
expert Q&A
03/25/2024

Peter G. Jacobs, PhD

Peter G. Jacobs, PhD
In this Q&A, study author Peter G. Jacobs, PhD, discusses the results of his team’s recent study examining the potential of combining wearable fitness sensor data with automated insulin delivery systems...
03/25/2024
Expert Q&A
Expert Q&A
03/23/2024
James F. List, MD, PhD
Based on findings from the Phase 3 A DUE study, Janssen Research & Development, LLC recently submitted a New Drug Application to the FDA seeking approval of an investigational once-daily, single-tablet...
03/23/2024
Expert Q&A
Expert Q&A
03/23/2024
James F. List, MD, PhD
Based on findings from the Phase 3 A DUE study, Janssen Research & Development, LLC recently submitted a New Drug Application to the FDA seeking approval of an investigational once-daily, single-tablet...
03/23/2024
Expert Q&A
Expert Q&A
03/23/2024
James F. List, MD, PhD
Based on findings from the Phase 3 A DUE study, Janssen Research & Development, LLC recently submitted a New Drug Application to the FDA seeking approval of an investigational once-daily, single-tablet...
03/23/2024
Expert Q&A
Expert Q&A
03/23/2024
James F. List, MD, PhD
Based on findings from the Phase 3 A DUE study, Janssen Research & Development, LLC recently submitted a New Drug Application to the FDA seeking approval of an investigational once-daily, single-tablet...
03/23/2024
Expert Q&A
Expert Q&A
03/18/2024
The FDA approved the use of Pfizer’s bivalent prefusion f vaccine in older adults to protect against respiratory syncytial virus. A Pfizer spokesperson answered questions about the study that helped lead to...
03/18/2024
Expert Q&A
Expert Q&A
03/18/2024
The FDA approved the use of Pfizer’s bivalent prefusion f vaccine in older adults to protect against respiratory syncytial virus. A Pfizer spokesperson answered questions about the study that helped lead to...
03/18/2024
Expert Q&A
Expert Q&A
03/18/2024
The FDA approved the use of Pfizer’s bivalent prefusion f vaccine in older adults to protect against respiratory syncytial virus. A Pfizer spokesperson answered questions about the study that helped lead to...
03/18/2024